Kite Pharma, Inc. 4/A
4/A · Kite Pharma, Inc. · Filed Mar 17, 2016
Insider Transaction Report
Form 4/AAmended
Roberts Margo R
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2016-02-17$0.70/sh+8,625$6,038→ 17,723 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-02-17−8,625→ 63,750 totalExercise: $0.70Exp: 2023-10-07→ Common Stock (8,625 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-02-17−1,007→ 31,581 totalExercise: $17.00Exp: 2024-06-18→ Common Stock (1,007 underlying) - Exercise/Conversion
Common Stock
2016-02-17$17.00/sh+1,007$17,119→ 18,730 total
Footnotes (3)
- [F1]The Form 4 is being amended to report the exercise of the same number of shares from two separate stock options. The original Form 4 incorrectly showed that the entire exercise occurred under one of the stock options.
- [F2]25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
- [F3]25% of the 50,000 shares subject to the stock option vested and became exercisable on June 19, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.